{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-24-000130","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.759020+00:00","generated_at":"2026-05-30T15:22:42.590102+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nurix Therapeutics reports Q3 FY2024 net loss $49M, $0.67 per share; cash $457.5M","bullets":["Net loss $49.0M ($0.67 per share) vs $37.0M ($0.68 per share) in Q3 FY2023.","Collaboration revenue $12.6M, down from $18.5M, reflecting end of Gilead research term offset by Pfizer deal.","Cash and marketable securities $457.5M as of Aug 31, 2024, up from $452.5M at May 31, 2024.","NX-5948 Phase 1b expansion started in CLL, Waldenstrom's, follicular, marginal zone lymphoma; FDA Fast Track for CLL.","NX-2127 enrollment reinitiated with new chirally controlled drug product after FDA partial clinical hold lift."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-24-000130","json":"https://secwatch.observer/filing/0001549595-24-000130.json","markdown":"https://secwatch.observer/filing/0001549595-24-000130.md","text":"https://secwatch.observer/filing/0001549595-24-000130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000130/0001549595-24-000130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000130/nrix-20241011.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T15:22:42.590102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}